Research Article
Epidemiological and Economic Evaluation of a Pilot Prostate Cancer Screening Program
Table 1
Serum PSA levels, free PSA, ProPSA, and PHI in men of Pavlodar region screened for PCa within 2013–2017.
| Year | Number of patients examined for PSA | Results of PSA test | Free PSA & ProPSA | PHI 25 and above | Number of identified diseases (N40, N41) | Number of identified PCa | <3.1 ng/ml | 3.1–7.8 ng/ml | >7.8 ng/ml | 2–4 points according to Gleason | 5–7 points according to Gleason | 8–10 points according to Gleason |
| 2013 | 9888 | 9504 | 331 | 53 | 129 | 91 | 196 | 8 | 5 | 0 | 2014 | 11666 | 11250 | 320 | 96 | 265 | 200 | 279 | 16 | 6 | 8 | 2015 | 9322 | 8877 | 367 | 78 | 268 | 151 | 355 | 4 | 1 | 2 | 2016 | 8821 | 8426 | 322 | 73 | 188 | 153 | 204 | 4 | 5 | 11 | 2017 | 9637 | 9177 | 339 | 121 | 185 | 142 | 214 | 4 | 6 | 9 |
| Total | 49334 | 47234 | 1679 | 421 | 1035 | 737 | 1248 | 36 | 23 | 30 |
|
|